Cite
HARVARD Citation
Jackisch, C. et al. (n.d.). 1945 Phase III HannaH study of subcutaneous or intravenous trastuzumab for HER2-positive early breast cancer: Exploratory subgroup analyses of pathological complete response and 3-year event-free survival according to body weight and anti-drug antibody status. European journal of cancer. pp. S313-S314. [Online].